Press Release : Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021

 
   Geneva, Switzerland, March 9, 2021 -- 
https://www.globenewswire.com/Tracker?data=eDgRdXBH0zcHD-qg8Me75BVxFrrDHW3plIaY_Ty2x6h1MVxTAJZQv3PscPhTyZuDa4ZdknM58s6D_B-WdaYPmL90Y146B7xExBnEA2lCOMw= 
Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company 
pioneering allosteric modulation-based drug discovery and development, 
announced today that it will issue its full-year 2020 financial results 
on Thursday March 11, 2021.  Tim Dyer, CEO, Roger Mills, CMO and Robert 
Lütjens, Head of Discovery Biology will provide a business update 
and review its pipeline during a teleconference and webcast for 
investors, analysts and the media on Thursday, March 11, 2021 at 16:00 
CET (15:00 GMT / 10:00 EST / 07:00 PST). 
 
   Title:                Addex to announce full-year 2020 financial results 
 
   Date:               March 11, 2021 
 
   Time:               16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST). 
 
   Joining the Conference Call: 
 
   1: In the 10 minutes prior to the call start time, call the appropriate 
participant dial-in number. 
 
   Dial-In Numbers: 
 
 
   -- Switzerland                               [phone] 
 
   -- UK                                 [phone] 
 
   -- U.S.A                                           [phone] 
 
   -- Other Countries 
      https://arkadinuk.sharefile.com/share/view/s0e04fcb522ce4024872b3086835672ec 
 
 
 
   2: Provide the Operator with the Participation Pin Code: 92320595# 
 
 
   Link to live event online: 
 
   1: In the 10 minutes prior to the call start time, sign in online by 
following this 
https://www.globenewswire.com/Tracker?data=8NdmSbtRuFs1n4qG4ro-kIXe0WSLXUaHZjJ2--yJlBZYRvnRAtIHIw50Yf6MmZGO-wdyB9IVvM-RANoImwAJnHbYMf76P4heRcLQn5JoFGXBkFyKgeLYBrPJO1be8c7ZDUhKFrL3YNLOOLq20U1NZ-2lzF5bNnuWECl5UNpOZivK-QwpntBBLn96Wya57gYx 
Webex link. 
 
   2: Password: Welcome 
 
   About Addex Therapeutics: 
 
   https://www.globenewswire.com/Tracker?data=eDgRdXBH0zcHD-qg8Me75PKFfo4ahup2WlPIMjOVzKi1NGh4xE2S-MnaHIVoGiYnJ490PYJNCRzHfGvKvvC6MSwEEUBpwaO4gufjlVfPqWs= 
Addex Therapeutics is a clinical-stage pharmaceutical company focused on 
the development and commercialization of an emerging class of novel 
orally available small molecule drugs known as allosteric modulators for 
neurological disorders. Allosteric modulators offer several potential 
advantages over conventional non-allosteric molecules and may offer an 
improved therapeutic approach to conventional "orthosteric" small 
molecule or biological drugs. Addex's allosteric modulator drug 
discovery platform targets receptors and other proteins that are 
recognized as essential for therapeutic intervention. Addex's lead drug 
candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is 
poised to start a pivotal registration clinical trial for Parkinson's 
disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also 
investigating dipraglurant's therapeutic use in blepharospasm (a type of 
dystonia), for which a clinical trial is expected to be initiated in H1 
2021. Addex's third clinical program, ADX71149 (mGlu2 positive 
allosteric modulator or PAM), developed in collaboration with Janssen 
Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept 
clinical study for the treatment of epilepsy in Q2 2021. Addex's GABAB 
PAM program has been licensed to Indivior PLC who are focused on 
development for the treatment of addiction. Preclinical programs include 
GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild 
neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 
PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss 
Exchange and the NASDAQ Capital Market and trades under the ticker 
symbol "ADXN". 
 
   Press Contacts: 
 
 
 
 
Tim Dyer                          Mike Sinclair                 James Carbonara 
 Chief Executive Officer           Partner, Halsin Partners      Hayden IR 
 Telephone: [phone]          [phone]           (646)-755-7412 
 55                                mailto:[e-mail]   mailto:[e-mail] 
 mailto:[e-mail]   [e-mail]          [e-mail] 
 [e-mail] 
--------------------------------  ----------------------------  -------------------------- 
 
   Forward Looking Statements: 
 
   This press release contains forward-looking statements within the 
meaning of the Private Securities Litigation Reform Act of 1995, as 
amended, including in respect of the anticipated initiation of clinical 
trials. The words "may," "will," "could," "would," "should," "expect," 
"plan," "anticipate," "intend," "believe," "estimate," "predict," 
"project," "potential," "continue," "target" and similar expressions are 
intended to identify forward-looking statements, although not all 
forward-looking statements contain these identifying words. Any 
forward-looking statements in this press release, are based on 
management's current expectations and beliefs and are subject to a 
number of risks, uncertainties and important factors that may cause 
actual events or results to differ materially from those expressed or 
implied by any forward-looking statements contained in this press 
release, including, without limitation, uncertainties related to market 
conditions. These and other risks and uncertainties are described in 
greater detail in the section entitled "Risk Factors" in Addex 
Therapeutics' Annual Report on Form 20-F for the year ended December 31, 
2019, as filed with the SEC on April 27, 2020, the prospectus related to 
the global offering and other filings that Addex Therapeutics may make 
with the SEC in the future. Any forward-looking statements contained in 
this press release represent Addex Therapeutics' views only as of the 
date hereof and should not be relied upon as representing its views as 
of any subsequent date. Addex Therapeutics explicitly disclaims any 
obligation to update any forward-looking statements. 
 
 
 
 

(END) Dow Jones Newswires

March 09, 2021 01:00 ET (06:00 GMT)